ORIGINAL ARTICLE

Immunochemical faecal occult blood tests in primary care and the risk of delay in the diagnosis of colorectal cancer

CECILIA HÖGBERG1, PONTUS KARLING2, JÖRGEN RUTEGÅRD3, MIKAEL LILJA1 & THOMAS LJUNG4

1Department of Public Health and Clinical Medicine, Unit of Clinical Research Centre – Östersund, Umeå University, Sweden, 2Department of Public Health and Clinical Medicine, Medicine/Gastroenterology, Umeå University, Sweden, 3Department of Surgical and Perioperative Sciences, Umeå University, Sweden, 4Department of Health Sciences, Mid Sweden University, Sweden

Abstract

Objective. To evaluate the value, risks, and shortcomings of immunochemical faecal occult blood tests (iFOBTs) in the diagnosis of colorectal cancer (CRC) and adenomas with high-grade dysplasia (HGD) in patients initially presenting to primary care. Design. A retrospective population-based study. Setting and subjects. All 495 cases of CRC and adenomas with HGD diagnosed in the county of Jämtland, Sweden from 2005 to 2009. Results. Of 495 patients 323 (65%) initially presented to primary care. IFOBTs were performed in 215 of 323 (67%) patients. The sensitivity of iFOBT for CRC and adenomas with HGD was 88% (83% when patients with a history of rectal bleeding were excluded). Of 34 patients with anaemia found en passant, 10 had negative iFOBTs. Time to diagnosis was longer for patients with negative iFOBTs (p < 0.0005). Conclusion. IFOBT might be helpful in selecting which patients to refer for colonoscopy. However, iFOBT has a limited sensitivity as a diagnostic test for CRC and adenomas with HGD. Relying only on iFOBT for colonoscopy referral could delay diagnosis, especially for patients with anaemia found en passant.

Key Words: Colorectal neoplasms, diagnosis, general practice, occult blood, signs and symptoms, Sweden

Introduction

Worldwide, colorectal cancer (CRC) is the third most common cancer in men and the second most common in women, and in Sweden the third most common cancer in both sexes [1,2]. Colorectal adenomas with high-grade dysplasia (HGD) and a diameter over one centimetre have an increased risk of developing into cancer [3]. The majority of patients with CRC first consult primary care physicians [4]. Symptoms associated with CRC (rectal bleeding, a change in bowel habits, diarrhoea, constipation, abdominal pain) are common reasons for seeking medical advice in primary care but most people experiencing these symptoms do not have a malignant disease [5–9]. Deciding which patients to refer for further investigation is challenging, and reliable tests would help with this selection.

Faecal occult blood tests (FOBTs) are commonly used in primary care in Sweden as a point-of-care analysis to help determine whether further investigation is needed. Earlier guaiac-based tests have mostly been replaced by immunological faecal occult blood tests (iFOBTs). The latter are specific for human haemoglobin, do not require dietary instructions, and can also be qualitative or quantitative with the possibility of setting different cut-off levels. Many studies have reported on the use of guaiac-based FOBTs and iFOBTs for CRC screening [10–15]. IFOBT is now the method recommended in Europe for this purpose [16]. In spite of frequent use, there are few studies concerning FOBTs and iFOBTs and the clinical consequences of the test results in symptomatic patients in primary care [17]. One study on guaiac-based FOBTs found a limited sensitivity for CRC and that diagnosis could be delayed [18]. Another study indicated that iFOBTs were of doubtful use in clinical situations [19].

The aim of the present study was to evaluate the value, risks, and shortcomings of iFOBTs obtained in primary care in the diagnosis of CRC and
adenomas with HGD. The latter were included as they are important precursors to cancer and are recorded in the Swedish Cancer Registry.

Material and methods

In Sweden all clinicians and pathologists are obliged to report the diagnoses of CRC and adenomas with HGD to the Swedish Cancer Registry. Patients aged 18 and older residing in Jämtland, with these diagnoses reported from 2005 to 2009, were identified from the Regional Cancer Registry [20]. Jämtland is a sparsely populated county with one hospital performing all endoscopies and all surgical treatments for CRC and adenomas for its 126,600 inhabitants. There is no screening programme for CRC. Data, including free text entries, were extracted from electronic medical records in Vårdadministrativ Systemutveckling (VAS), used by all primary care centres and the hospital. All records were examined by one of the authors (CH).

When more than one CRC or adenoma with HGD was detected as a consequence of the same investigation, the clinically most severe diagnosis was chosen and considered as one case.

The start of an investigation was identified as when the patient first consulted a primary health care physician with symptoms or when the physician first initiated an investigation because of an abnormal examination or laboratory finding, leading to the diagnosis of CRC or adenoma with HGD.

Symptoms and signs were classified as gastrointestinal symptoms (a change in bowel habits, diarrhoea, constipation, and abdominal pain) with or without rectal bleeding, and/or other symptoms and signs. Rectal bleeding was defined as visible blood in the stools and/or on toilet paper.

The presence of anaemia at the start of the investigation was recorded. Anaemia was defined as a haemoglobin level < 134 g/l in men and < 117 g/l in women (the reference values used in the county’s laboratories).

Patients with a visible rectal cancer or adenoma observed by the referring clinician were registered.

The date of clinical diagnosis was identified as when the CRC or adenoma was diagnosed through endoscopy, double-contrast barium enema, computed tomography, or surgery. Whether the patient had planned treatment after referral from primary care or was diagnosed after emergency admission was registered.

Data concerning all iFOBTs delivered by the patients beginning two years before the clinical diagnosis were registered. The retrospective period for symptoms and signs was also two years. Two years is the interval recommended for screening in Europe [16].

The faecal samples were analysed at the primary care centres with Actim Fecal Blood (Oy Medix Biocheema Ab, Finland), a visually read, qualitative, immunological dipstick test with a sensitivity of 50 μg haemoglobin per litre of faecal solution corresponding to 25–50 μg per gram of faeces [21]. Traditionally in Sweden a set of iFOBTs consists of three samples. Sets with one or more positive samples were regarded as positive, and sets with only negative samples as negative. Patients with first negative and at later consultations positive sets of iFOBTs were regarded as negative, as the first set was likely to have had the greatest influence on decisions about further investigation.

To calculate the sensitivity, specificity, and negative and positive predictive values we used the total number of patients who had iFOBTs analysed in the county’s primary care centres from 2008 and 2009, excluding patients that were diagnosed with CRC or adenomas with HGD within two years after the test was done. The yearly number of iFOBTs analysed during this period did not differ from the previous three years. Using the statistical program SPSS version 18 (Chicago, IL, USA) we performed chi-squared tests, and when adjusting for age and sex an ANCOVA.

Results

During the study period, 294 patients with CRC and 29 patients with adenomas with HGD initially consulted primary care (Figure 1). The mean age was 71.3 (33–96) years and 48% were women.

iFOBTs were analysed in 215 (67%) patients (mean age 71.6 years, 47% women) with an average of 2.8 (1–6) samples per set of iFOBTs, in total 662 samples (Table I). In 12 patients two sets of iFOBTs, and in four patients three sets of iFOBTs were anal-
Of these 16, four had first negative and after an interval of six to 15 months positive tests. Haemoglobin was analysed in all but 12 patients (Table II). Of these 12, eight had a history of rectal bleeding and all had planned treatment after referral from primary care.

Of the patients where iFOBTs were analysed 12% had negative results (Table III). In 34 patients where iFOBTs were performed because of anaemia found en passant, for example at annual check-ups for diabetes, no symptoms of gastrointestinal disease or anaemia were mentioned. Ten of these had negative iFOBTs, with a mean haemoglobin value of 107 g/l in cases with positive, and 103 g/l in cases with negative results.

The time from the start of the investigation to diagnosis was significantly longer for patients with negative than with positive iFOBTs (Figure 2). Adjusting for age and sex and exclusion of adenomas with HGD did not change these results. For 19% of the patients the investigation started more than 180 days before diagnosis.

Overall 27% were diagnosed after emergency admission: 26% of those with no iFOBT performed, 23% of those with positive iFOBTs, and 64% of those with negative iFOBTs.

Abnormal rectal findings were observed by the referring physician at endoscopy in 72 of the 124 patients with rectal neoplasms. In 36 (50%) of the patients with rectal neoplasms iFOBTs were performed before the endoscopy and two were negative.

The estimated sensitivity of iFOBT for CRC and adenomas with HGD was 88% with all indications for iFOBTs included. A total of 4013 patients (those with cancers and adenomas with HGD excluded) had iFOBTs performed in the county from 2008 to 2009, of which 1061 had positive sets of iFOBTs. This results in an estimated specificity of 74%, positive predictive value of 6.7%, and negative predictive value of 99.7%. Excluding patients with rectal bleeding the estimated sensitivity was 82.9%, and also excluding patients with anaemia it was 83.3%.

**Discussion**

Our main finding in this population-based study of 323 patients with colorectal malignancies was that iFOBTs were often negative in patients with symptoms or anaemia. Almost one-third of the patients with anaemia found en passant had negative iFOBTs, with mean haemoglobin values equivalent for patients with negative and positive tests, indicating that less total blood loss did not explain the negative results. A longer diagnostic delay was seen in patients with negative iFOBTs compared with patients who had positive iFOBTs.

---

**Table I. Immunochemical faecal occult blood test (iFOBT) results in primary care stratified for tumour localizations in 323 patients with CRC and adenomas with HGD.**

|                      | Right-side colon | Left-side colon | Rectum | Not specified | Total |
|----------------------|-----------------|----------------|--------|--------------|-------|
| No iFOBT             | 18 ± 0\(^1\)    | 24 ± 2\(^1\)   | 52 ± 10\(^1\) | 2 ± 0\(^1\) | 96 ± 12\(^1\) |
| Positive iFOBT       | 57 ± 1\(^1\)    | 61 ± 6\(^1\)   | 54 ± 6\(^1\)  | 3 ± 2\(^1\)  | 175 ± 15\(^1\) |
| Negative iFOBT       | 13 ± 1\(^1\)    | 5 ± 1\(^1\)    | 2 ± 0\(^1\)   | 3 ± 0\(^1\)  | 23 ± 2\(^1\)   |

Note: \(^1\)Adenomas with high-grade dysplasia (HGD).
Diagnostic delays in patients with negative tests have also been found in a study on guaiac-based FOBTs [18]. It seems probable that doctors use iFOBTs as a means for deciding on further investigation, and are misled by negative results. In our study, the diagnostic delays were most evident for patients with anaemia found en passant, and for symptomatic patients without rectal bleeding or anaemia. These subgroups, where a reliable test in clinical practice would be of greatest value, had a sensitivity of 71% and 83%, respectively. As mentioned above, iFOBT can be useful in primary care, but negative results cannot be entirely trusted.

Of the patients whose investigation started in primary care, 27% had an emergency admission, which is similar to findings in other studies [25,26]. We found that the group with negative iFOBTs had a larger proportion (64%) of emergency admissions, indicating that a missed diagnosis in many cases resulted in acute illness.

Our study has several weaknesses. It is retrospective and iFOBTs were not analysed in all patients. In the group where no iFOBTs were performed, it is probable that a higher percentage had more evident symptoms and was referred without further investigation. The symptoms retrieved from the patients’ records

Table II. Immunochemical faecal occult blood test (iFOBT) results stratified for the presence of anaemia at the start of investigations in primary care in 323 patients with CRC and adenomas with HGD.

|                  | Anaemia | No anaemia | Unknown | Total     |
|------------------|---------|------------|---------|-----------|
|                  | n = 124 | n = 159    | n = 11  | n = 294   |
| No iFOBT         | 23 + 1  | 65 + 10    | 8 + 1   | 96 + 12   |
| Positive iFOBT   | 86 + 2  | 86 + 13    | 3 + 0   | 175 + 15  |
| Negative iFOBT   | 15 + 0  | 8 + 2      | 0 + 0   | 23 + 2    |

Notes: 1Adenomas with high-grade dysplasia (HGD).
Anaemia was defined as haemoglobin concentration < 134 g/l in men and < 117 g/l in women.

Table III. Symptoms and signs at the start of investigations in primary care and results of immunochemical faecal occult blood tests (iFOBTs) in 323 patients with CRC and adenomas with HGD.

|                  | Rectal bleeding | Other than rectal bleeding, no anaemia | Anaemia, no symptoms | Anaemia with rectal bleeding excluded | All patients |
|------------------|-----------------|---------------------------------------|----------------------|-------------------------------------|--------------|
|                  | n = 116 + 14    | n = 83 + 12                           | n = 33 + 1           | n = 62 + 2                          | n = 294 + 29 |
| No iFOBT performed | 56 + 5^2        | 29 + 6^2                              | 0 + 0^2              | 11 + 1^2                            | 96 + 12^2    |
| iFOBT performed   | 60 + 9^2        | 54 + 6^2                              | 33 + 1^2             | 51 + 1^2                            | 198 + 17^2   |
| of which positive iFOBT | 60 + 9^2      | 46 + 4^2                              | 23 + 1^2             | 46 + 1^2                            | 175 + 15^2   |
| of which negative iFOBT | 0 + 0^2        | 8 + 2^2                               | 10 + 0^2             | 5 + 0^2                             | 23 + 2^2     |

Notes: 1These were gastrointestinal symptoms n = 80 + 11^2, or only other symptoms or signs n = 3 + 1^2.
2Adenomas with high-grade dysplasia (HGD).
Anaemia was defined as haemoglobin concentration < 134 g/l in men and < 117 g/l in women.

To our knowledge, this is the first study to investigate the contribution of iFOBTs performed in primary care to the diagnosis of CRC.

In this study iFOBTs were analysed in primary care in 40% of the total 538 recorded cases of CRC and adenomas with HGD, which is considerably more than the 18% of cases of CRC in a Swedish study on guaiac-based FOBTs analysed in primary care [18]. Apart from the possibility that doctors in Jämtland use iFOBTs more frequently, or that the county’s residents initially consult primary care to a larger extent, the fact that all primary care centres were included in our study could contribute to this difference.

Generally, rectal bleeding is considered an alarm symptom whereby endoscopy should be performed [8,22]. Here, iFOBT before referral seems unnecessary. In patients with symptoms with low risk of CRC, iFOBT could be of value to select patients for endoscopy [23]. However, one should be aware that iFOBTs in our study were negative in approximately every sixth case of CRC without rectal bleeding. Using an iFOBT with higher sensitivity would probably give fewer false negative results, but would also most likely result in lower specificity [24]. As this study is retrospective, iFOBTs were not performed in all patients, and probably not all patients with false-positive iFOBTs were examined with colonoscopy or barium contrast enema, the sensitivity and specificity should be interpreted with caution. However, studies concerning iFOBTs used in secondary care have shown similar results [15].
were probably not all the symptoms mentioned. On the other hand it is likely that doctors registered what they considered most important for their decision-making. Validation of data extraction was not done, but all records were analysed by the same person. The study also has its strengths. The population was well defined, and the coverage in the Swedish Cancer Registry is almost complete [27]. All patient records are kept in the same computer system, and were examined by one person. IFOBTs were performed in two-thirds of the patients, the same method was used in all analyses, and the date of diagnosis is exact.

In conclusion, iFOBT might be helpful in selecting patients to be investigated with endoscopy. However, one should be aware of the limited sensitivity of iFOBT as a diagnostic test, for CRC and adenomas with HGD, especially in patients with anaemia found en passant. IFOBT in combination with certain symptoms and other laboratory tests could, it is hoped, improve the diagnosis of CRC. Further research concerning this is needed.

**Declaration of interest**

The authors report no conflict of interest. The authors alone are responsible for the content and writing of the paper.

**References**

[1] GLOBOCAN 2008. Available at: http://globocan.iarc.fr (accessed 8 February 2013).
[2] Cancer incidence in Sweden 2011. National Board of Health and Welfare Available at: http://www.socialstyrelsen.se (accessed 8 February 2013).
[3] Toll AD, Fabius D, Hyslop T, Pequignot E, DiMarino AJ, Infantolino A, et al. Prognostic significance of high-grade dysplasia in colorectal adenomas. Colorectal Dis 2010;13:370–3.
[4] Mansson J, Bjorkelund C, Hultborn R. Symptom pattern and diagnostic work-up of malignancy at first symptom presentation as related to level of care: A retrospective study from the primary health care centre area of Kungsbacka, Sweden. Neoplasma 1999;46:93–9.
[5] Carlsson L, Hakansson A, Nordenskjold B. Common cancer-related symptoms among GP patients: Opportunistic screening in primary health care. Scand J Prim Health Care 2001;19:199–203.
[6] Vandvik PO, Kristensen P, Aabakken L, Farup PG. Abdominal complaints in general practice: Diagnoses and characteristics of patients. Scand J Prim Health Care 2004;22:157–62.
[7] Svendsen RP, Stovring H, Hansen BL, Kragstrup J, Sondergaard J, Jarbol DE. Prevalence of cancer alarm symptoms: A
population-based cross-sectional study. Scand J Prim Health Care 2010;28:132–7.

[8] Astin M, Griffin T, Neal RD, Rose P, Hamilton W. The diagnostic value of symptoms for colorectal cancer in primary care: A systematic review. Br J Gen Pract 2011;61:e231–43.

[9] Thompson MR, Perera R, Senapati A, Dodds S. Predictive value of common symptom combinations in diagnosing colorectal cancer. Br J Surg 2007;94:1260–5.

[10] Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 1993;328:1365–71.

[11] Hardecastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472–7.

[12] Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467–71.

[13] Zorzi M, Fedato C, Grazzini G, Stocco FC, Banovich F, Bortoli A, et al. High sensitivity of five colorectal screening programmes with faecal immunochemical test in the Veneto Region, Italy. Gut 2011;60:944–9.

[14] Zhu MM, Xu XT, Nie F, Tong JL, Xiao SD, Ran ZH. Comparison of immunochemical and guaiac-based fecal occult blood test in screening and surveillance for advanced colorectal neoplasms: A meta-analysis. J Dig Dis 2010;11:148–60.

[15] Rozen P, Comaneshter D, Levi Z, Hazazi R, Vilkin A, Maoz E, et al. Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use. Cancer 2010;116:2115–25.

[16] European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis. Luxembourg: Publications Office of the European Union; 2011. Available at: http://bookshop.europa.eu.

[17] Jellena P, van der Windt DAWM, Bruinvelds DJ, Mallen CD, van Weyenberg SJB, Mulder CJ, et al. Value of symptoms and additional diagnostic tests for colorectal cancer in primary care: Systematic review and meta-analysis. BMJ 2010;340:c1269–c.

[18] Gillberg A, Ericsson B, Granstrom F, Olsson LI. A population-based audit of the clinical use of faecal occult blood testing in primary care for colorectal cancer. Colorectal Dis 2012;14:e539–46.

[19] Högberg C, Asplund R. Många feces-Hb-test till liten nytta. Immunkemisk metod ger dålig diagnostik, visar primärvårdsstudie (Small benefit of many feces-Hb tests. Low diagnostic value of the immunochemical method according to a primary health care study). English summary. Lakartidningen 2010;107:1372–5.

[20] Regionalt cancercentrum norr. Available at: http://www.cancercentrum.se/norr/.

[21] Obtained from Oy Medix Biochemica Ab. Available at: http://www.medixbiochemica.com.

[22] NICE clinical guidelines. Referral guidelines for suspected cancer. Available at: http://publications.nice.org.uk (accessed 8 February 2013).

[23] McDonald PJ, Digby J, Innes C, Strachan JA, Carey FA, Steele RJ, et al. Low faecal haemoglobin concentration potentially rules out significant colorectal disease. Colorectal Dis 2013;15:e151–9.

[24] Guittet L, Bouvier V, Mariotte N, Vallee JP, Arsene D, Boutreux S, et al. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 2007;56:210–14.

[25] Trickett JP, Donaldson DR, Bearn PE, Scott HJ, Hassall AC. A study on the routes of referral for patients with colorectal cancer and its effect on the time to surgery and pathological stage. Colorectal Dis 2004;6:428–31.

[26] Barrett J, Jiwa M, Rose P, Hamilton W. Pathways to the diagnosis of colorectal cancer: An observational study in three UK cities. Fam Pract 2006;23:15–9.

[27] Barlow L, Westergren K, Holmberg L, Talback M. The completeness of the Swedish Cancer Register: A sample survey for year 1998. Acta Oncol 2009;48:27–33.